PD-1 inhibitors play an important role in the treatment of patients with mNSCLC and, alongside their development, predictive biomarker testing for tumour genomic aberrations in such genes as EGFR or ALK, and PD-L1 expression have become mandatory in most European countries [11]. This evidence concerns the gene EGFR and neoplasm.